PF-2341066 (Crizotinib) is an orally-available, ATP-competitive, aminopyridine-based dual inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectively. [1] A kinase selectivity panel shows that PF-2341066 is selective against most tyrosine and serine-threonine kinases, with modest activity with Ron (IC50, 80 nM). [2] PF-2341066 inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, and invasion of human tumor cells in vitro at IC50s of 5 to 20 nM.

PF-2341066 has been shown to be effective in osteosarcoma growth [3] and anaplastic large-cell lymphomas [4].